Clinical Trials Logo

Esophagitis clinical trials

View clinical trials related to Esophagitis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06381583 Completed - Esophageal Cancer Clinical Trials

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

EMERALD
Start date: April 15, 2023
Phase:
Study type: Observational

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.

NCT ID: NCT05813561 Completed - Reflux Esophagitis Clinical Trials

The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

Start date: December 30, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.

NCT ID: NCT05488405 Completed - Clinical trials for Eosinophilic Esophagitis

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis

NCT ID: NCT05485779 Completed - Clinical trials for Eosinophilic Esophagitis (EoE)

SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects

Start date: July 20, 2022
Phase: Phase 1
Study type: Interventional

The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients.

NCT ID: NCT05444543 Completed - Clinical trials for Eosinophilic Esophagitis

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

Start date: November 17, 2021
Phase: Phase 4
Study type: Interventional

The purpose of our research study is to assess whether patients with EoE who have achieved control of their disease on topical Fluticasone or Budesonide are able to cycle or take breaks from their treatment with continued remission of their EoE. There will be 30 participants enrolled in this study. There will be 15 patients who will stay on steroid therapy every day and 15 patients who will cycle their steroid therapy on and off to help us compare the two groups. The cycling group will cycle their steroid therapy in a three-months on three-months off fashion.

NCT ID: NCT05129670 Completed - Esophagitis Clinical Trials

Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This investigation is designed to evaluate the acid neutralisation action of a new test product versus unmatched placebo.

NCT ID: NCT05084963 Completed - Clinical trials for Eosinophilic Esophagitis

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Start date: October 29, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)

NCT ID: NCT05083312 Completed - Clinical trials for Eosinophilic Esophagitis

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

FLUTEEN
Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.

NCT ID: NCT05055128 Completed - Erosive Esophagitis Clinical Trials

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.

NCT ID: NCT05050188 Completed - Erosive Esophagitis Clinical Trials

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

Start date: June 24, 2021
Phase: Phase 1
Study type: Interventional

This will be a Phase I, randomized, double-blind, positive- and placebo-controlled study to evaluate the safety, tolerability, and PK/PD of multiple oral doses of H008 in healthy adult subjects. Two dose levels of H008 at 20 mg and 40 mg will be studied in two sequential cohorts. Each cohort will be enrolled with 12 subjects (8 on H008, 2 on placebo and 2 on positive control drug). Subjects are only allowed to participate in one of the two cohorts. Both the investigational product and placebo will be given in a double blinded manner, while the positive control drug will be given in an open-label manner.Dose escalation to the next cohort will be permitted only when safety data until follow-up and PK data until 48 hours post-last dose, from all subjects in previous cohorts are reviewed, and the investigational product is deemed well tolerated. The study will consist of a screening period, a baseline period, a 7-day repeated-dose period and a safety follow-up period.